The importance of gastric secretion in the feedback control of interdigestive and postprandial pancreatic secretion in rats.
Previous studies demonstrated that pancreatic enzyme secretion in rats is stimulated by the diversion of pancreatic juice from the duodenum or by the inhibition of pancreatic proteinases in the intestinal lumen but little attention has been paid to the role of gastric secretion in this stimulation. This study, carried out on conscious rats with large gastric (GF) and pancreatic fistulas, confirms that diversion of pancreatic juice in rats with the GF closed results in the progressive stimulation of pancreatic secretion reaching the maximum similar to that induced by exogenous CCK. When the GF was kept open, the diversion resulted in only small increment in pancreatic secretion and this was accompanied by progressive increase in gastric acid outputs. Similar amounts of HCl (25-400 mumol/h) instilled intraduodenally (i.d.) in rats with the GF open fully reproduced the increase in pancreatic secretion observed after the diversion of pancreatic juice and this effect was completely abolished by the pretreatment with L-364,718, a specific CCK receptor antagonist. Pretreatment with omeprazole to suppress completely gastric acid secretion in the diverted state resulted in a decline in pancreatic secretion similar to that observed after opening the GF. Camostate given in graded doses (6-200 mg/kg) either i.d. or s.c. in rats with pancreatic juice returned to the duodenum caused a dose-dependent increase in pancreatic secretion, but after opening the GF or after omeprazole this increase was reduced by about 50% while after L-364,718 it was abolished. This study provides evidence that gastric secretion plays an important role in the pancreatic response to diversion of pancreatic juice or inhibition of luminal proteinases (but not to feeding) and the elimination of gastric acid reduces this response.
Konturek
S J
SJ
Institute of Physiology, Academy of Medicine, Krakow, Poland.
Krzyzek
E
E
Bilski
J
J
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology; D020109:Devazepide; D004386:Duodenum / Q000502:physiology*; D004435:Eating / Q000502:physiology*; D004952:Esters; D005402:Fistula; D016670:Gabexate / Q000031:analogs & derivatives*; D005750:Gastric Juice / Q000378:metabolism*; D006146:Guanidines / Q000494:pharmacology; D006851:Hydrochloric Acid / Q000378:metabolism; D008297:Male; D009853:Omeprazole / Q000494:pharmacology; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism*; D010189:Pancreatic Juice / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors
D001570:Benzodiazepinones; D004952:Esters; D006146:Guanidines; D011480:Protease Inhibitors; D011949:Receptors, Cholecystokinin; C034532:camostat; D016670:Gabexate; D020109:Devazepide; D009853:Omeprazole; D006851:Hydrochloric Acid